About Us
Management Team
Board of Directors
Scientific Advisory Board
Program Partners
See about us
See Who We Are
Pipeline
Oncology
Ophthalmology
Inflammatory Disease
See All Pipeline
See Scientific Publications
Patients
A Message to Our Patients
Our Areas of Focus
Clinical Trials
See Patients
Investors & Media
News & Events
Press Releases
Events
Presentations
Stock
Stock Quote & Chart
Analyst Coverage
Governance
Documents & Charters
Management Team
Board Of Directors
Committee Composition
Board Diversity Matrix
Financials
SEC Filings
IR REsources
Investor FAQs
Email Alerts
Contact IR
see all Investor information
Careers
Contact
EN
中文
EN
中文
About Us
Who We Are
Management Team
Board of Directors
Scientific Advisory Board
Program Partners
Scientific Publications
Pipeline
Oncology
Ophthalmology
Inflammatory Disease
Patients
Message to Our Patients
Our Areas of Focus
Clinical Trials
Investors
News & Events
Press Releases
Events
Presentations
Stock
Stock Quote & Chart
Analyst Coverage
Governance
Documents & Charters
Management Team
Board of Directors
Committee Composition
Board Diversity Matrix
Financials
SEC Filings
IR Resources
Contact IR
Investor FAQs
Email Alerts
Contact IR
Careers
Contact
Scientific Publications
Cutting-edge research
Oncology
Efficacy and Safety of Infigratinib in Patients with Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and FGFR2 Gene Amplification
October 23, 2023
-
European Society for Medical Oncology (ESMO) Congress 2023
Efficacy and Safety of Infigratinib in Patients with Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and FGFR2 Gene Amplification
October 23, 2023
-
European Society for Medical Oncology (ESMO) Congress 2023